|Place of Origin:||China|
|Minimum Order Quantity:||1KG|
|Packaging Details:||Aluminum foil bag|
|Payment Terms:||L/C, D/A, D/P, T/T, Western Union, MoneyGram，Alibaba Assurance Order|
|Grade:||Medicine Grade||Appearance:||White Crystalline Powder|
99% Loratadine Powder,
Anti Allergy Loratadine Powder,
API Pharmaceutical 79794-75-5
CAS 79794-75-5 Anti Allergy Raw Material Powder 99% Loratadine Powder
The Introductction of Loratadine
Loratadine is a commonly used anti-allergic drug, a second-generation long-acting tricyclic antihistamine, with fast onset of action and strong effect, does not contain hormones, and is metabolized to the more active desloratadine after human absorption, which inhibits histamine-induced allergic symptoms through competitive inhibition of histamine H1 receptors, without obvious anticholinergic and central inhibitory effects.
Loratadine is well absorbed orally, metabolized rapidly and extensively in the liver, and eliminated via urine and feces. It has a rapid onset of action, with some patients showing effects within 30 min, a tmax of 1.5-2 h, and an elimination half-life of 8-14 h. The active metabolite, descarboxymethoxy loratadine (DCL), has a half-life of 17-24 h. The half-life may be longer in the elderly and in patients with liver disease. The binding rate of loratadine to plasma proteins is 97% to 99%, and 73% to 76% for DCL. About 27% of loratadine is excreted in the urine after 24h of administration, about 40% is eliminated in the urine after 10 days, and 42% is excreted in the stool. Little is secreted with milk, so the drug is safe for use during lactation.
Loratadine is used clinically to relieve symptoms associated with allergic rhinitis, such as sneezing, runny and itchy nose as well as itching and burning sensation of the eyes.
Loratadine is also used to relieve the symptoms of chronic urticaria and other allergic skin diseases.
Toxicology: No mutagenic, non-teratogenic effects in animal testing.
Common adverse reactions include headache, drowsiness, fatigue, dry mouth and blurred vision, decreased or increased blood pressure, palpitations, syncope, hyperkinesia, altered liver function, jaundice, hepatitis, hepatic necrosis, alopecia, seizures, breast enlargement, erythema multiforme, and systemic allergic reactions.
Drug interactions: Drugs that inhibit the function of hepatic drug metabolizing enzymes can slow down the metabolism of this product, such as itraconazole, ketoconazole, and 400 mg of ketoconazole taken together daily can increase the plasma concentration of this product and its active metabolite, descarboxyethylchloratadine, but no electrocardiographic changes were observed. The metabolism of loratadine can also be inhibited by administration with macrolide antibiotics, cimetidine, theophylline, etc.
|Product Name||Loratadine||Batch No.||HNB-230202|
|Issuing Date||2023.02.02||Expiry Date||2025.02.01|
|Test items||Test Iimit||Results|
|Identification||Infrared spectrum should conform||Conforms|
|B. should conform||Conforms|
|Sieve analysis||100% pase||Conforms|
|Residual Solvents||< 100ppm||Conforms|
|Loss on drying||≤1.0%||0.12%|
|Residue on ignition||≤1.0%||0.09%|
|Microbiological Tests||Total plate count: ≤1000cfu/g||Conforms|
|Moulds and Yeasts: ≤100cfu/g||Conforms|
|Conclusion||The above material complies with USP32 standard|